Weight Management
Semaglutide
Semaglutide is a GLP-1 receptor agonist that has been extensively studied for weight management and metabolic health. Clinical trials have demonstrated significant reductions in body weight when combined with lifestyle interventions, with sustained effects observed over multiple years.
Key research findings
Average weight reduction of 14.9% over 68 weeks in the landmark STEP 1 trial
Cardiovascular risk reduction of 20% in patients with obesity and preexisting heart disease (SELECT trial)
Weight loss sustained for up to 4 years with continued use
Higher doses (7.2 mg) achieved approximately 20.7% weight reduction in the STEP UP trial
Oral formulation (25 mg) achieved 13.6% weight reduction in the OASIS 4 trial
Published research & clinical studies
STUDY 1
STEP 1 — Once-Weekly Semaglutide in Adults with Overweight or Obesity
New England Journal of Medicine, 2021
Landmark Phase 3 RCT (n=1,961) showing 14.9% mean body weight reduction vs 2.4% with placebo over 68 weeks.
STUDY 2
SELECT — Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
New England Journal of Medicine, 2023
Major cardiovascular outcomes trial (n=17,604) demonstrating 20% reduction in cardiovascular events.
STUDY 3
Long-term Weight Loss Effects of Semaglutide in the SELECT Trial
Nature Medicine, 2024
4-year follow-up showing sustained weight loss of 10.2% and waist circumference reduction of 7.7 cm
STUDY 4
OASIS 4 — Oral Semaglutide 25 mg in Adults with Overweight or Obesity
New England Journal of Medicine, 2025
Phase 3 trial of oral formulation showing 13.6% mean weight reduction at 64 weeks.
STUDY 5
STEP UP — Once-weekly Semaglutide 7.2 mg in Adults with Obesity
Lancet Diabetes & Endocrinology, 2025
Phase 3b trial showing 20.7% weight loss with higher-dose semaglutide, superior to 2.4 mg.
Research disclaimer: The studies referenced above are provided for educational purposes only. They represent published scientific research and do not constitute medical advice, treatment recommendations, or endorsement of any specific therapy. Velacore Health does not provide medical services or prescribe medications. All decisions regarding peptide therapy are made solely by independent, licensed healthcare providers. Always consult with your healthcare provider before considering any therapy.